Drug intelligence / Profile preview

IBI343 + mFOLFOX

Development stage: Unknown
Lead developer: Innovent Biologics
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI343 + mFOLFOX is a combination therapy being developed by Innovent Biologics for the treatment of CLDN18.2-expressing solid tumors, including gastric, gastroesophageal junction, and pancreatic cancers. IBI343 is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) utilizing a cleavable linker to attach an exatecan payload (a topoisomerase I inhibitor) with a drug-to-antibody ratio (DAR) of 4. The mFOLFOX component is a standard chemotherapy regimen consisting of oxaliplatin, leucovorin, and 5-fluorouracil. The combination aims to leverage the targeted delivery of IBI343 and its bystander killing effect alongside the systemic cytotoxic activity of mFOLFOX. It is currently being evaluated in Phase 1 clinical trials (NCT05458219).

Other names: IBI343 in combination with mFOLFOXIBI-343 in combination with mFOLFOXIBI 343 in combination with mFOLFOXIBI343 plus mFOLFOXIBI-343 plus mFOLFOXIBI 343 plus mFOLFOX

Targets

TOP1 (DNA Topoisomerase I)Claudin 18.2

Beyond the preview

Go deeper on IBI343 + mFOLFOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI343 + mFOLFOX.

Explore the full profile